

TURNING HIGH-COST CLAIMS INTO HIGH-VALUE CARE

A Guide to Effectively Navigating the Most Serious & Expensive Medical Conditions



September 3, 2025

About PHM



18 years

of experience managing the most serious and complex cases across a wide range of clinical issues


Multidisciplinary teams composed of **65+** experienced **PhD research scientists and clinicians** personally connect employees to leading experts for comprehensive, high-quality support

>100 employers

15+ industries


Deep relationships and access to top medical experts:

- PHM Consulting Physician Partners
- Specialist Expert Opinion Network
- Curated Treating Provider Referrals



Focusing on the Most Consequential Cases





7 of the top 10 cases



costing over \$500,000+

are cancer

Employers are placing increased emphasis on addressing complex conditions and high-cost cases

The high-cost cases are where the deficiencies of our health care system are most consequential in terms of unnecessary cost and quality deficiencies



Closing Gaps in Care

Treating serious and complex conditions in the U.S. healthcare system reveals deficiencies

-	Adequate information about the clinical issue(s)	+	Comprehensive clinical assessment
-	Sufficient time with the patient	+	Patient advocacy and support system
-	Knowledge of the latest data-supported treatment advances	+	PhD-led research to identify precisely the right answers
-	Coordination with other physicians or providing logistical support	+	Comprehensive care coordination and logistical support
-	Referrals to the best specialists for the specific condition	+	Clinical and institutional independence and vast network of providers





- $\Delta \Delta$ 3,000+ attorneys and staff worldwide
- ? 15 offices across US, Europe, and Asia
- (139,000+ pro bono hours in 2024)
- 14 consecutive years on A-list of elite firms
- Top 3 Law Firm by *The American Lawyer* for 9 years





ROPES & GRAY

The challenges we set out to solve





4,200 covered members employees + dependents on health plan

Our Health Challenges

of population accounts for ~40% of plan spend

high-cost cases drive **~20%** of plan costs

of the population have active cancer and drive ~15% of plan spend

Value to Our Colleagues

- Trusted partner
- Faster access to the right care
- Compassionate care
- Family support
- Navigating a complex system

Value to Our Firm

- Take care of our people
- High colleague satisfaction
- Avoided unnecessary intervention
- More control over high-cost claims
- Innovator in health benefits

The Partnership Timeline





2024 2025 2026

Partnership Begins "Soft Launch"

CANCER CARE

U.S. Health Plan Members

Program Launch

CANCER CARE

U.S. Health Plan Members

+

HEALTH ADVISORY

Global Partners/Chiefs

Program Expansion

CANCER CARE

U.S. Health Plan Members

+

HEALTH ADVISORY

Global Partners/Chiefs

+

SERIOUS & COMPLEX CARE


U.S. Health Plan Members

Partnership Success: Collaboration in all aspects including contracting, ecosystem integration, claims data collection, employee engagement, and issue resolution

Diverse Set of Conditions Addressed in Q1 2025



Health Condition (Non-Cancer)	%
Congenital disorder	20%
Injury	20%
Genitourinary disorder	20%
Respiratory disorder	10%
Orthopedic, musculoskeletal, or connective tissue disorder	10%
Ear disorder	10%
Endocrine or metabolic disorder	10%



Cancer Type	%
Breast cancer	29%
Suspicion of cancer / elevated cancer risk	29%
Pancreatic cancer	14%
Leukemia	14%
Multiple myeloma	14%





Advisory

5%

Of members typically drive 60% of spend

60%

Of spend tied to top 5 cancers

6x

Higher rate of acting on molecular profiling tests

Clinical

30%

Diagnosis changed

70%

Modification of treatment plans for optimal care

4x

Improvement in access to clinical trials

2-4x

Improvement in survival for late-stage cancers

Financial

20%

Average savings per complex case

15%

PHM clients avoided unnecessary treatments

2:1

Return on investment

Of employers say PHM improved employee health

92%

Of employers extremely satisfied with PHM experience






Precision Medicine Transforms Cancer Care

- 32-year-old woman
- Stage 2 high-risk breast cancer
- Phase 3 clinical trial
- Effective combination of targeted therapy and hormone therapy

Hannah's clinical story





Hannah is cancer free today

PHM Impact

Connect with Us





Julie D. Blume
Director of Total Rewards
Ropes & Gray LLP
Julie.Blume@ropesgray.com



Natalya Gertsik, PhD VP, Partnerships Private Health Management ngertsik@privatehealth.com

Please visit the PHM exhibit booth 19



PHM Applied Health Intelligence Whitepaper on Cancer



We're here when you need us.

See our Wall of Purpose